{"groups":[{"description":"Patients receive vismodegib 150 mg orally (PO) daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Vismodegib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never Start Protocol Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Mutation Status Not Confirmed"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"15"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other Complicating Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"comment":"Primary efficacy analysis set","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients with Patched-1 (PTCH1) and Smoothened (SMO) alterations (excluding basal cell carcinoma) were assigned to sub-protocol T. The mutation status was determined by an NCI-MATCH approved laboratory for 19 patients in this arm, these cases had to be confirmed to be used in primary analysis.","recruitmentDetails":"Subprotocol T was activated on February 25, 2016. Thirty-four patients were enrolled on EAY131-T between June 20, 2016, and September 22, 2020. Fifteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 19 on the basis of the outside assay results."}